Overview
- Jim Cramer said he will not recommend Recursion Pharmaceuticals until he sees a clear proof of concept, calling the stock a poor performer.
- In a March call-in segment he urged investors to hold off, and the stock is down about 30% since that earlier comment, according to the report.
- He acknowledged NVIDIA’s involvement with the company but maintained that recent share performance has been disappointing.
- Recursion is a clinical-stage biotech using AI-driven methods in drug discovery with programs spanning cancers and other conditions and no product sales to date.
- The article presenting Cramer’s remarks also promotes alternative AI stock ideas, reflecting a blend of news and investment marketing.